Potential use of EGFR-targeted molecular therapies for tumor suppressor CYLD-negative and poor prognosis oral squamous cell carcinoma with chemoresistance.
Kanemaru A, Shinriki S, Kai M, Tsurekawa K, Ozeki K, Uchino S, Suenaga N, Yonemaru K, Miyake S, Masuda T, Kariya R, Okada S, Takeshita H, Seki Y, Yano H, Komohara Y, Yoshida R, Nakayama H, Li JD, Saito H, Jono H.
Kanemaru A, et al. Among authors: shinriki s.
Cancer Cell Int. 2022 Nov 15;22(1):358. doi: 10.1186/s12935-022-02781-x.
Cancer Cell Int. 2022.
PMID: 36376983
Free PMC article.